AKBA
NASDAQ · Biotechnology
Akebia Therapeutics Inc
$1.41
+0.05 (+3.68%)
Financial Highlights (FY 2026)
Revenue
244.34M
Net Income
-5,533,194
Gross Margin
82.9%
Profit Margin
-2.3%
Rev Growth
-6.9%
D/E Ratio
5.94
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.9% | 82.9% | 34.7% | 34.7% |
| Operating Margin | 9.9% | 9.0% | -4.5% | -4.8% |
| Profit Margin | -2.3% | -2.2% | -5.9% | -6.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 244.34M | 262.39M | 65.59M | 81.13M |
| Gross Profit | 202.58M | 217.55M | 22.75M | 28.15M |
| Operating Income | 24.31M | 23.50M | -2,955,557 | -3,890,676 |
| Net Income | -5,533,194 | -5,347,803 | -3,878,355 | -4,942,326 |
| Gross Margin | 82.9% | 82.9% | 34.7% | 34.7% |
| Operating Margin | 9.9% | 9.0% | -4.5% | -4.8% |
| Profit Margin | -2.3% | -2.2% | -5.9% | -6.1% |
| Rev Growth | -6.9% | -6.9% | +11.6% | -8.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 163.92M | 163.92M | 21.85M | 26.69M |
| Total Equity | 27.61M | 27.61M | 127.43M | 136.15M |
| D/E Ratio | 5.94 | 5.94 | 0.17 | 0.20 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 21.18M | 21.60M | -4,128,349 | -4,627,733 |
| Free Cash Flow | — | — | -1,979,346 | -2,914,255 |